NEW YORK, May 15, 2025--(BUSINESS WIRE)--OS Therapies (NYSE-A: OSTX) ("OS Therapies" or "the Company"), a clinical-stage immunotherapy and Antibody Drug Conjugate (ADC) biopharmaceutical company, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback